Application of quantitative real-time reverse transcription-PCR in assessing drug efficacy against the intracellular pathogen Cryptosporidium parvum in vitro

Antimicrobial Agents and Chemotherapy

Volumn 49, Issue 11, 2005, Pages 4437-4442

  Cai, Xiaomin ^a   Woods, Keith M ^b   Upton, Steve J ^b   Zhu, Guan ^a  

^a TEXAS A AND M UNIVERSITY   (United States)

^b KANSAS STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL DEHYDROGENASE; DNA; NITAZOXANIDE; PAROMOMYCIN; PYRAZOLE DERIVATIVE; RNA 18S;

ANTIPROTOZOAL ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CRYPTOSPORIDIUM PARVUM; DRUG EFFICACY; DRUG TARGETING; HUMAN; HUMAN CELL; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RELIABILITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STRAIN DIFFERENCE;

ANIMALS; CRYPTOSPORIDIUM PARVUM; PYRAZOLES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, PROTOZOAN; RNA, RIBOSOMAL, 18S;

EID: 27644512737     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.49.11.4437-4442.2005     Document Type: Article

References (31)

1. Abrahamsen, M. S., and A. A. Schroeder. 1999. Characterization of intracellular Cryptosporidium parvum gene expression. Mol. Biochem. Parasitol. 104:141-146.
2. Abrahamsen, M. S., T. J. Templeton, S. Enomoto, J. E. Abrahante, G. Zhu, C. A. Lancto, M. Deng, C. Liu, G. Widmer, S. Tzipori, G. A. Buck, P. Xu, A. T. Bankier, P. H. Dear, B. A. Konfortov, H. F. Spriggs, L. Iyer, V. Anantharaman, L. Aravind, and V. Kapur. 2004. Complete genome sequence of the apicomplexan, Cryptosporidium parvum. Science 304:441-445.
3. Andersson, P., J. Kvassman, A. Lindstrom, B. Olden, and G. Pettersson. 1981. Effect of pH on pyrazole binding to liver alcohol dehydrogenase. Eur. J. Biochem. 114:549-554.
4. Cai, X., C. A. Lancto, M. S. Abrahamsen, and G. Zhu. 2004. Intron-containing beta-tubulin transcripts in Cryptosporidium parvum cultured in vitro. Microbiology 150:1191-1195.
5. Chappell, C. L., and P. C. Okhuysen. 2002. Cryptosporidiosis. Curr. Opin. Infect. Dis. 15:523-527.
6. Di Giovanni, G. D., and M. W. LeChevallier. 2005. Quantitative-PCR assessment of Cryptosporidium parvum cell culture infection. Appl. Environ. Microbiol. 71:1495-1500.
7. Eklund, H., J. P. Samama, and L. Wallen. 1982. Pyrazole binding in crystalline binary and ternary complexes with liver alcohol dehydrogenase. Biochemistry 21:4858-4866.
8. Fayer, R., U. Morgan, and S. J. Upton. 2000. Epidemiology of Cryptosporidium: transmission, detection and identification. Int. J. Parasitol. 30:1305-1322.
9. Feierman, D. E., and A. I. Cederbaum. 1987. Oxidation of the alcohol dehydrogenase inhibitor pyrazole to 4-hydroxypyrazole by microsomes. Effect of cytochrome P-450 inducing agents. Drug Metab. Dispos. 15:634-639.
10. Fox, L. M., and L. D. Saravolatz. 2005. Nitazoxanide: a new thiazolide antiparasitic agent. Clin. Infect. Dis. 40:1173-1180.
11. Gargala, G., A. Delaunay, L. Favennec, P. Brasseur, and J. J. Ballet. 1999. Enzyme immunoassay detection of Cryptosporidium parvum inhibition by sinefungin in sporozoite infected HCT-8 enterocytic cells. Int. J. Parasitol. 29:703-709.
12. Gargala, G., A. Delaunay, X. Li, P. Brasseur, L. Favennec, and J. J. Ballet. 2000. Efficacy of nitazoxanide, tizoxanide and tizoxanide glucuronide against Cryptosporidium parvum development in sporozoite-infected HCT-8 enterocytic cells. J. Antimicrob. Chemother. 46:57-60.
13. MacDonald, L. M., K. Sargent, A. Armson, R. C. Thompson, and J. A. Reynoldson. 2002. The development of a real-time quantitative-PCR method for characterisation of a Cryptosporidium parvum in vitro culturing system and assessment of drug efficacy. Mol. Biochem. Parasitol. 121:279-282.
14. Marshall, R. J., and T. P. Flanigan. 1992. Paromomycin inhibits Cryptosporidium infection of a human enterocyte cell line. J. Infect. Dis. 165:772-774.
15. Morgan-Ryan, U. M., A. Fall, L. A. Ward, N. Hyjawi, I. Sulaiman, R. Payer, R. C. Thompson, M. Olson, A. Lal, and L. Xiao. 2002. Cryptosporidium hominis n. sp. (Apicomplexa: Cryptosporidiidae) from Homo sapiens. J. Eukaryot. Microbiol. 49:433-440.
16. Nesterenko, M. V., and S. J. Upton. 1996. A rapid microcentrifuge procedure for purification of Cryptosporidium sporozoites. J. Microbiol. Methods 25:87-89.
17. Pereira, E. F., Y. Aracava, R. S. Aronstam, E. J. Barreiro, and E. X. Albuquerque. 1992. Pyrazole, an alcohol dehydrogenase inhibitor, has dual effects on N-methyl-D-aspartate receptors of hippocampal pyramidal cells: agonist and noncompetitive antagonist. J. Pharmacol. Exp. Ther. 261:331-340.
18. Perkins, M. E., T. W. Wu, and S. M. Le Blancq. 1998. Cyclosporin analogs inhibit in vitro growth of Cryptosporidium parvum. Antimicrob. Agents Chemother. 42:843-848.
19. Phelps, K. K., D. S. Lindsay, S. S. Sumner, and R. Payer. 2001. Immunohistochemistry based assay to determine the effects of treatments on Cryptosporidium parvum viability. J. Eukaryot. Microbiol. 48(Suppl.):40S-41S.
20. Theodos, C. M., J. K. Griffiths, J. D'Onfro, A. Fairfield, and S. Tzipori. 1998. Efficacy of nitazoxanide against Cryptosporidium parvum in cell culture and in animal models. Antimicrob. Agents Chemother. 42:1959-1965.
21. Trivic, S., and V. Leskovac. 1994. Kinetic mechanism of yeast alcohol dehydrogenase activity with secondary alcohols and ketones. Indian J. Biochem. Biophys. 31:387-391.
22. Tzipori, S., and G. Widmer. 2000. The biology of Cryptosporidium. Contrib. Microbiol. 6:1-32.
23. Upton, S. J., M. Tilley, and D. B. Brillhart. 1995. Effects of select medium supplements on in vitro development of Cryptosporidium parvum in HCT-8 cells. J. Clin. Microbiol. 33:371-375.
24. Wilhelm, J., and A. Pingoud. 2003. Real-time polymerase chain reaction. Chem. Biochem. 4:1120-1128.
25. Woods, K. M., M. V. Nesterenko, and S. J. Upton. 1995. Development of a microtitre ELISA to quantify development of Cryptosporidium parvum in vitro. FEMS Microbiol. Lett. 128:89-94.
26. Woods, K. M., M. V. Nesterenko, and S. J. Upton. 1996. Efficacy of 101 antimicrobials and other agents on the development of Cryptosporidium parvum in vitro. Ann. Trop. Med. Parasitol. 90:603-615.
27. Xu, P., G. Widmer, Y. Wang, L. S. Ozaki, J. M. Alves, M. G. Serrano, D. Puiu, P. Manque, D. Akiyoshi, A. J. Mackey, W. R. Pearson, P. H. Dear, A. T. Bankier, D. L. Peterson, M. S. Abrahamsen, V. Kapur, S. Tzipori, and G. A. Buck. 2004. The genome of Cryptosporidium hominis. Nature 431:1107-1112.
28. You, X., M. J. Arrowood, M. Lejkowski, L. Xie, R. F. Schinazi, and J. R. Mead. 1996. A chemiluminescence immunoassay for evaluation of Cryptosporidium parvum growth in vitro. FEMS Microbiol. Lett. 136:251-256.
29. You, X., M. J. Arrowood, M. Lejkowski, L. Xie, R. F. Schinazi, and J. R. Mead. 1996. In vitro evaluation of anticryptosporidial agents using MDCK cell culture and chemiluminescence immunoassay. J. Eukaryot. Microbiol. 43:87S.
30. Zhu, G., and J. S. Keithly. 1997. Molecular analysis of a P-type ATPase from Cryptosporidium parvum. Mol. Biochem. Parasitol. 90:307-316.
31. Zhu, G., J. S. Keithly, and H. Philippe. 2000. What is the phylogenetic position of Cryptosporidium? Int. J. Syst. Evol. Microbiol. 50:1673-1681.